Drugs targeting cancer metabolism and unmet need in HER2-positive breast cancer, as well as cytotoxic agents wrapped into novel delivery technologies, are among the top 10 unpartnered oncology drugs to be showcased at Windhover’s Therapeutic Area Partnerships meeting in Boston from Nov. 28-30.
Each year at the TAP meeting, expert consultants present their take of the hottest unpartnered assets available for licensing in a range of therapeutic areas, including oncology, cardiovascular medicine, neuroscience...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?